Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Hair loss
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 383569
Licensor grants a non-exclusive, sublicensable, transferable license under the Licensed Know-How to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Field in the Territory.
Licensor grants a non-exclusive, sublicensable, transferable license under the FTO Patents to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Territory.
Licensor will use Commercially Reasonable Efforts to transfer to Licensee all items of Licensed Know-How, including Manufacturing know-how.
For Research, Development, and Manufacturing of Licensed Products Scope & Diligence, Licensee will have sole control and responsibility for the Research, Development, Manufacture and Commercialization of all Licensed Products.
Licensor FTO Patents mean any Patents that
— are not Licensor Licensed Patents or Licensor Related Patents;
— cover manufacturing processes, including intermediates, or formulations of Compounds or Licensed Products, or uses of Compounds or Licensed Products for hair growth or the prevention of hair loss; and
— Licensor or its Affiliates Controls as of the Effective Date or during the Term.
— Licensors compound known as setipiprant ;
— all other compounds covered by the Patents listed; and
— the salts, enantiomers, racemates, polymorphs, crystalline forms, non-crystalline forms, hydrates, solvates, esters, conjugates, metabolites and prodrugs of the compounds.
— the gene encoding the chemoattractant receptor-homologous molecule expressed on Th2 cells for any species, which molecule is also known as GPR44 or DP2;
— the protein encoded by such gene; and
— all subtypes, mutants and variants thereof.
CRTH2 Antagonists means any molecule with a primary mechanism of action of antagonizing CRTH2.
Patents are titled/relate to Tetrahydropyridoindole derivatives.
IPSCIO Record ID: 211864
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient. The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.
This agreement pertains to drug discovery.
IPSCIO Record ID: 383570
The patents are
— Prostaglandin D2 Synthase and its Products as Cause of Hair Loss and Target for Therapy;
— Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.